Autologous lung-derived mesenchymal stem cell transplantation in experimental emphysema

Area of Science:

• Regenerative Medicine
• Pulmonary Medicine
• Stem Cell Biology

Background:

• Emphysema is a chronic lung disease characterized by alveolar destruction.
• Current treatments for emphysema are limited and do not restore lost lung function.
• Mesenchymal stem cells (MSCs) show potential for tissue regeneration.

Purpose of the Study:

• To assess the therapeutic potential of autologous lung-derived mesenchymal stem cells (LMSCs) for regenerating functional lung tissue in an experimental emphysema model.
• To evaluate the safety and efficacy of endoscopic LMSC transplantation in sheep.

Main Methods:

• Autologous LMSCs were derived from transbronchial biopsies, cultured, and labeled.
• LMSCs were delivered via an endoscopic scaffold containing fibrinogen, fibronectin, and poly-L-lysine.
• Sheep with experimental emphysema received LMSC-loaded scaffolds or scaffold alone (control).
• In vivo assessments included clinical toxicity, lung physiology, CT scanning for tissue mass, scintigraphy for perfusion, and histology.

Main Results:

• LMSC transplantation was well tolerated with no significant clinical toxicity.
• A 4-week follow-up showed increased lung tissue mass and perfusion in LMSC-treated animals compared to controls.
• Histology confirmed cell retention, increased cellularity, and enhanced extracellular matrix content in treated lungs.
• Labeled cells were found in alveolar septa and peribronchiolar interstitium, with some uptake by phagocytes.

Conclusions:

• Endoscopic delivery of autologous LMSCs is a feasible and potentially effective strategy for lung regeneration in emphysema.
• LMSC transplantation can improve lung tissue mass and perfusion, suggesting functional recovery.
• Further research is warranted to optimize LMSC delivery and survival for clinical application in emphysema treatment.